2
|
Frew J, Smith A, Penas PF, Ellis E, Foley P, Rubel D, McMeniman E, Marshman G, Saunders H, Veysey E, Nicolopolous J, Spelman L, Gebauer K. Australasian hidradenitis suppurativa management guidelines. Australas J Dermatol 2024. [PMID: 39578415 DOI: 10.1111/ajd.14388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2024] [Revised: 08/22/2024] [Accepted: 11/13/2024] [Indexed: 11/24/2024]
Abstract
Hidradenitis Suppurativa is a burdensome inflammatory skin disease with significant quality of life impact. These management guidelines were developed to direct appropriate clinical management in the Australasian context. A systematic review was used for the basis of the consensus guidelines. Thirteen clinical experts were involved in a modified Delphi consensus process to develop the guidelines and treatment algorithms. Overall management strategies include appropriate severity assessment of disease and comorbidities, multimodal therapy with systemic and local treatments, and evidence-based progression along the therapeutic ladder in the event of inadequate response. Sequential monotherapy with antibiotics and/or single agent therapy is discouraged and aggressive treatment of moderate to severe disease to capture the window of opportunity is highly emphasised. Specific considerations in the setting of disease comorbidities, pregnancy and breastfeeding are also addressed. Overall, the complex nature of HS requires a complex and multimodal therapeutic response with medical, physical and surgical therapies to achieve best patient outcomes.
Collapse
Affiliation(s)
- John Frew
- The Skin Hospital, Sydney, New South Wales, Australia
- Department of Dermatology, Liverpool Hospital, Sydney, New South Wales, Australia
- University of New South Wales, Sydney, New South Wales, Australia
| | - Annika Smith
- The Skin Hospital, Sydney, New South Wales, Australia
- Department of Dermatology, Westmead Hospital, Sydney, New South Wales, Australia
- University of Sydney, Sydney, New South Wales, Australia
| | - Pablo Fernandez Penas
- Department of Dermatology, Westmead Hospital, Sydney, New South Wales, Australia
- University of Sydney, Sydney, New South Wales, Australia
| | - Elisabeth Ellis
- Flinders Medical Centre, Adelaide, South Australia, Australia
| | - Peter Foley
- Skin Health Institute Melbourne, Melbourne, Victoria, Australia
- St Vincent's Hospital, Melbourne, Victoria, Australia
| | - Diana Rubel
- Canberra Hospital, Canberra, Australian Capital Territory, Australia
| | - Erin McMeniman
- Princess Alexandria Hospital, Brisbane, Queensland, Australia
| | - Gillian Marshman
- Flinders Medical Centre, Adelaide, South Australia, Australia
- Flinders University, Adelaide, South Australia, Australia
| | | | - Emma Veysey
- St Vincent's Hospital, Melbourne, Victoria, Australia
| | | | - Linda Spelman
- Queensland Institute of Dermatology, Brisbane, Queensland, Australia
| | - Kurt Gebauer
- Fremantle Dermatology, Fremantle, Western Australia, Australia
| |
Collapse
|
3
|
Ávila de Almeida C, Haui P, Martins Costa F, Povill J, Alcantara Martins P, Loureiro M, Barbosa Luz F, Ribeiro G, Werner H, Canella Moraes Do Carmo C. Essential Considerations for Radiologists in Diagnosing Hidradenitis Suppurativa. Radiographics 2024; 44:e240066. [PMID: 39480703 DOI: 10.1148/rg.240066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2024]
Abstract
Hidradenitis suppurativa, also referred to as inverse acne, manifests as a persistent inflammatory skin disorder characterized by lesions such as deep nodules, abscesses, sinus tracts, and fibrotic scars. These manifestations predominantly occur in skin folds and intertriginous areas, notably in the axillary, inguinal, perianal, perineal, and inframammary regions. Due to similarities with other conditions in its initial stages, accurate diagnosis of hidradenitis suppurativa is often delayed, sometimes spanning several years. Diagnosis relies on identifying specific morphologic features (such as deep, inflamed, and painful nodules; sinus tracts; and scars), considering the affected sites (skin folds and areas with apocrine glands), and recognizing the chronic nature of the condition (persistent course with periods of exacerbation and remission). There are no definitive biologic or pathologic diagnostic tests, and biopsy of the affected area is not necessary. Treatment varies based on severity and may include topical and systemic antibiotics, hormonal therapy, immunomodulators, and surgery. Due to associated pain, increased site sensitivity, secretion drainage, odor, and scarring, this condition can have a negative psychosocial impact. Imaging studies, including high-frequency US and MRI with subsequent three-dimensional reconstruction, serve as valuable tools for precise staging, monitoring disease activity, and preoperative assessment. Currently, high-frequency US stands as the preferred method, incorporating sonographic classifications, while MRI and thee-dimensional imaging represent an emerging and promising approach. Imaging helps identify the extent of sinus tracts, assess involvement dimensions in advanced disease stages, and monitor proposed treatments. ©RSNA, 2024 Supplemental material and the slide presentation from the RSNA Annual Meeting are available for this article.
Collapse
Affiliation(s)
- Carolina Ávila de Almeida
- From the Department of Radiology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil (C.A.d.A., F.M.C.); Department of Radiology, Centro Universitário de Valença, Valença, Brazil (C.A.d.A.); Diagnósticos da América S/A, Rio de Janeiro, Brazil (C.A.d.A., P.H., F.M.C., J.P., P.A.M., H.W., C.C.M.D.C.); Department of Dermatology, Hospital Universitário Pedro Ernesto da Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil (M.L.); Department of Dermatology, Universidade Federal Fluminense, Niteroi, Brazil (F.B.L.); Bio Design Laboratory, Pontifícia Universidade Católica, Rio de Janeiro, Brazil (G.R., H.W., C.C.M.D.C.); Department of Radiology, Universidade Federal Fluminense, Niteroi, Brazil (C.C.M.D.C.); Department of Radiology, University Hospital Clementino Fraga Filho, R. Prof. Rodolpho Paulo Rocco, 255- Cidade Universitária, Rio de Janeiro, RJ 21941-617, Brazil (C.A.d.A.)
| | - Priscilla Haui
- From the Department of Radiology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil (C.A.d.A., F.M.C.); Department of Radiology, Centro Universitário de Valença, Valença, Brazil (C.A.d.A.); Diagnósticos da América S/A, Rio de Janeiro, Brazil (C.A.d.A., P.H., F.M.C., J.P., P.A.M., H.W., C.C.M.D.C.); Department of Dermatology, Hospital Universitário Pedro Ernesto da Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil (M.L.); Department of Dermatology, Universidade Federal Fluminense, Niteroi, Brazil (F.B.L.); Bio Design Laboratory, Pontifícia Universidade Católica, Rio de Janeiro, Brazil (G.R., H.W., C.C.M.D.C.); Department of Radiology, Universidade Federal Fluminense, Niteroi, Brazil (C.C.M.D.C.); Department of Radiology, University Hospital Clementino Fraga Filho, R. Prof. Rodolpho Paulo Rocco, 255- Cidade Universitária, Rio de Janeiro, RJ 21941-617, Brazil (C.A.d.A.)
| | - Flavia Martins Costa
- From the Department of Radiology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil (C.A.d.A., F.M.C.); Department of Radiology, Centro Universitário de Valença, Valença, Brazil (C.A.d.A.); Diagnósticos da América S/A, Rio de Janeiro, Brazil (C.A.d.A., P.H., F.M.C., J.P., P.A.M., H.W., C.C.M.D.C.); Department of Dermatology, Hospital Universitário Pedro Ernesto da Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil (M.L.); Department of Dermatology, Universidade Federal Fluminense, Niteroi, Brazil (F.B.L.); Bio Design Laboratory, Pontifícia Universidade Católica, Rio de Janeiro, Brazil (G.R., H.W., C.C.M.D.C.); Department of Radiology, Universidade Federal Fluminense, Niteroi, Brazil (C.C.M.D.C.); Department of Radiology, University Hospital Clementino Fraga Filho, R. Prof. Rodolpho Paulo Rocco, 255- Cidade Universitária, Rio de Janeiro, RJ 21941-617, Brazil (C.A.d.A.)
| | - Jessica Povill
- From the Department of Radiology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil (C.A.d.A., F.M.C.); Department of Radiology, Centro Universitário de Valença, Valença, Brazil (C.A.d.A.); Diagnósticos da América S/A, Rio de Janeiro, Brazil (C.A.d.A., P.H., F.M.C., J.P., P.A.M., H.W., C.C.M.D.C.); Department of Dermatology, Hospital Universitário Pedro Ernesto da Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil (M.L.); Department of Dermatology, Universidade Federal Fluminense, Niteroi, Brazil (F.B.L.); Bio Design Laboratory, Pontifícia Universidade Católica, Rio de Janeiro, Brazil (G.R., H.W., C.C.M.D.C.); Department of Radiology, Universidade Federal Fluminense, Niteroi, Brazil (C.C.M.D.C.); Department of Radiology, University Hospital Clementino Fraga Filho, R. Prof. Rodolpho Paulo Rocco, 255- Cidade Universitária, Rio de Janeiro, RJ 21941-617, Brazil (C.A.d.A.)
| | - Philippe Alcantara Martins
- From the Department of Radiology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil (C.A.d.A., F.M.C.); Department of Radiology, Centro Universitário de Valença, Valença, Brazil (C.A.d.A.); Diagnósticos da América S/A, Rio de Janeiro, Brazil (C.A.d.A., P.H., F.M.C., J.P., P.A.M., H.W., C.C.M.D.C.); Department of Dermatology, Hospital Universitário Pedro Ernesto da Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil (M.L.); Department of Dermatology, Universidade Federal Fluminense, Niteroi, Brazil (F.B.L.); Bio Design Laboratory, Pontifícia Universidade Católica, Rio de Janeiro, Brazil (G.R., H.W., C.C.M.D.C.); Department of Radiology, Universidade Federal Fluminense, Niteroi, Brazil (C.C.M.D.C.); Department of Radiology, University Hospital Clementino Fraga Filho, R. Prof. Rodolpho Paulo Rocco, 255- Cidade Universitária, Rio de Janeiro, RJ 21941-617, Brazil (C.A.d.A.)
| | - Mario Loureiro
- From the Department of Radiology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil (C.A.d.A., F.M.C.); Department of Radiology, Centro Universitário de Valença, Valença, Brazil (C.A.d.A.); Diagnósticos da América S/A, Rio de Janeiro, Brazil (C.A.d.A., P.H., F.M.C., J.P., P.A.M., H.W., C.C.M.D.C.); Department of Dermatology, Hospital Universitário Pedro Ernesto da Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil (M.L.); Department of Dermatology, Universidade Federal Fluminense, Niteroi, Brazil (F.B.L.); Bio Design Laboratory, Pontifícia Universidade Católica, Rio de Janeiro, Brazil (G.R., H.W., C.C.M.D.C.); Department of Radiology, Universidade Federal Fluminense, Niteroi, Brazil (C.C.M.D.C.); Department of Radiology, University Hospital Clementino Fraga Filho, R. Prof. Rodolpho Paulo Rocco, 255- Cidade Universitária, Rio de Janeiro, RJ 21941-617, Brazil (C.A.d.A.)
| | - Flavio Barbosa Luz
- From the Department of Radiology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil (C.A.d.A., F.M.C.); Department of Radiology, Centro Universitário de Valença, Valença, Brazil (C.A.d.A.); Diagnósticos da América S/A, Rio de Janeiro, Brazil (C.A.d.A., P.H., F.M.C., J.P., P.A.M., H.W., C.C.M.D.C.); Department of Dermatology, Hospital Universitário Pedro Ernesto da Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil (M.L.); Department of Dermatology, Universidade Federal Fluminense, Niteroi, Brazil (F.B.L.); Bio Design Laboratory, Pontifícia Universidade Católica, Rio de Janeiro, Brazil (G.R., H.W., C.C.M.D.C.); Department of Radiology, Universidade Federal Fluminense, Niteroi, Brazil (C.C.M.D.C.); Department of Radiology, University Hospital Clementino Fraga Filho, R. Prof. Rodolpho Paulo Rocco, 255- Cidade Universitária, Rio de Janeiro, RJ 21941-617, Brazil (C.A.d.A.)
| | - Gerson Ribeiro
- From the Department of Radiology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil (C.A.d.A., F.M.C.); Department of Radiology, Centro Universitário de Valença, Valença, Brazil (C.A.d.A.); Diagnósticos da América S/A, Rio de Janeiro, Brazil (C.A.d.A., P.H., F.M.C., J.P., P.A.M., H.W., C.C.M.D.C.); Department of Dermatology, Hospital Universitário Pedro Ernesto da Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil (M.L.); Department of Dermatology, Universidade Federal Fluminense, Niteroi, Brazil (F.B.L.); Bio Design Laboratory, Pontifícia Universidade Católica, Rio de Janeiro, Brazil (G.R., H.W., C.C.M.D.C.); Department of Radiology, Universidade Federal Fluminense, Niteroi, Brazil (C.C.M.D.C.); Department of Radiology, University Hospital Clementino Fraga Filho, R. Prof. Rodolpho Paulo Rocco, 255- Cidade Universitária, Rio de Janeiro, RJ 21941-617, Brazil (C.A.d.A.)
| | - Heron Werner
- From the Department of Radiology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil (C.A.d.A., F.M.C.); Department of Radiology, Centro Universitário de Valença, Valença, Brazil (C.A.d.A.); Diagnósticos da América S/A, Rio de Janeiro, Brazil (C.A.d.A., P.H., F.M.C., J.P., P.A.M., H.W., C.C.M.D.C.); Department of Dermatology, Hospital Universitário Pedro Ernesto da Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil (M.L.); Department of Dermatology, Universidade Federal Fluminense, Niteroi, Brazil (F.B.L.); Bio Design Laboratory, Pontifícia Universidade Católica, Rio de Janeiro, Brazil (G.R., H.W., C.C.M.D.C.); Department of Radiology, Universidade Federal Fluminense, Niteroi, Brazil (C.C.M.D.C.); Department of Radiology, University Hospital Clementino Fraga Filho, R. Prof. Rodolpho Paulo Rocco, 255- Cidade Universitária, Rio de Janeiro, RJ 21941-617, Brazil (C.A.d.A.)
| | - Clarissa Canella Moraes Do Carmo
- From the Department of Radiology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil (C.A.d.A., F.M.C.); Department of Radiology, Centro Universitário de Valença, Valença, Brazil (C.A.d.A.); Diagnósticos da América S/A, Rio de Janeiro, Brazil (C.A.d.A., P.H., F.M.C., J.P., P.A.M., H.W., C.C.M.D.C.); Department of Dermatology, Hospital Universitário Pedro Ernesto da Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil (M.L.); Department of Dermatology, Universidade Federal Fluminense, Niteroi, Brazil (F.B.L.); Bio Design Laboratory, Pontifícia Universidade Católica, Rio de Janeiro, Brazil (G.R., H.W., C.C.M.D.C.); Department of Radiology, Universidade Federal Fluminense, Niteroi, Brazil (C.C.M.D.C.); Department of Radiology, University Hospital Clementino Fraga Filho, R. Prof. Rodolpho Paulo Rocco, 255- Cidade Universitária, Rio de Janeiro, RJ 21941-617, Brazil (C.A.d.A.)
| |
Collapse
|
7
|
Ingram JR, Bates J, Cannings-John R, Collier F, Gibbons A, Harris C, Hood K, Howells L, Howes R, Leighton P, Riaz M, Rodrigues J, Stanton H, Thomas KS, Thomas-Jones E. Treatment of Hidradenitis Suppurativa Evaluation Study: the THESEUS prospective cohort study. Health Technol Assess 2023; 27:1-107. [PMID: 38149635 PMCID: PMC11017627 DOI: 10.3310/hwnm2189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2023] Open
Abstract
Background Hidradenitis suppurativa is a chronic inflammatory skin disease characterised by recurrent inflammatory lesions and skin tunnels in flexural sites such as the axilla. Deroofing of skin tunnels and laser treatment are standard hidradenitis suppurativa interventions in some countries but not yet introduced in the United Kingdom. Objective To understand current hidradenitis suppurativa management pathways and what influences treatment choices to inform the design of future randomised controlled trials. Design Prospective 12-month observational cohort study, including five treatment options, with nested qualitative interviews and an end-of-study consensus workshop. Setting Ten United Kingdom hospitals with recruitment led by dermatology and plastic surgery departments. Participants Adults with active hidradenitis suppurativa of any severity not adequately controlled by current treatment. Interventions Oral doxycycline 200 mg once daily; oral clindamycin and rifampicin, both 300 mg twice daily for 10 weeks initially; laser treatment targeting the hair follicle (neodymium-doped yttrium aluminium garnet or alexandrite); deroofing; and conventional surgery. Main outcome measures Primary outcome was the proportion of participants who are eligible, and hypothetically willing, to use the different treatment options. Secondary outcomes included proportion of participants choosing each of the study interventions, with reasons for their choices; proportion of participants who switched treatments; treatment fidelity; loss to follow-up rates over 12 months; and efficacy outcome estimates to inform outcome measure instrument responsiveness. Results Between February 2020 and July 2021, 151 participants were recruited, with two pauses due to the COVID-19 pandemic. Follow-up rates were 89% and 83% after 3 and 6 months, decreasing to 70% and 44% at 9 and 12 months, respectively, because pandemic recruitment delays prevented all participants reaching their final review. Baseline demographics included an average age of 36 years, 81% female, 20% black, Asian or Caribbean, 64% current or ex-smokers and 86% with a raised body mass index. Some 69% had moderate disease, 19% severe disease and 13% mild disease. Regarding the study's primary outcome, laser treatment was the intervention with the highest proportion (69%) of participants who were eligible and hypothetically willing to receive treatment, followed by deroofing (58%), conventional surgery (54%), the combination of oral clindamycin and rifampicin (44%) and doxycycline (37%). Considering participant willingness in isolation, laser was ranked first choice by the greatest proportion (41%) of participants. The cohort study and qualitative study demonstrated that participant willingness to receive treatment was strongly influenced by their clinician. Fidelity to oral doxycycline was only 52% after 3 months due to lack of effectiveness, participant preference and adverse effects. Delays receiving procedural interventions were common, with only 43% and 26% of participants commencing laser therapy and deroofing, respectively, after 3 months. Treatment switching was uncommon and there were no serious adverse events. Daily pain score text messages were initiated in 110 participants. Daily responses reduced over time with greatest concordance during the first 14 days. Limitations It was not possible to characterise conventional surgery due to a low number of participants. Conclusion The Treatment of Hidradenitis Suppurativa Evaluation Study established deroofing and laser treatment for hidradenitis suppurativa in the United Kingdom and developed a network of 10 sites for subsequent hidradenitis suppurativa randomised controlled trials. Future work The consensus workshop prioritised laser treatment and deroofing as interventions for future randomised controlled trials, in some cases combined with drug treatment. Trial registration This trial is registered as ISRCTN69985145. Funding This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 12/35/64) and is published in full in Health Technology Assessment; Vol. 27, No. 30. See the NIHR Funding and Awards website for further award information.
Collapse
Affiliation(s)
- John R Ingram
- Division of Infection and Immunity, Cardiff University, Cardiff, UK
| | - Janine Bates
- Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK
| | - Rebecca Cannings-John
- Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK
| | | | - Angela Gibbons
- Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK
| | - Ceri Harris
- Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK
| | - Kerenza Hood
- Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK
| | - Laura Howells
- Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK
| | - Rachel Howes
- Burns and Plastic Surgery, Stoke Mandeville Hospital, Aylesbury, UK
| | - Paul Leighton
- Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK
| | - Muhammad Riaz
- Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK
| | - Jeremy Rodrigues
- Burns and Plastic Surgery, Stoke Mandeville Hospital, Aylesbury, UK
- Warwick Clinical Trials Unit, University of Warwick, Warwick, UK
| | - Helen Stanton
- Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK
| | - Kim S Thomas
- Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK
| | | |
Collapse
|